Short answer: the side effects listed for MOTS-c are injection-site reactions, allergic or immune reactions, heart-rate changes, trouble sleeping, fever and low blood sugar, according to InCare, a clinic with locations in Tampa and Riverview. InCare says that list draws on early studies, related peptide research and patient reports. The one human study it names is of a related analogue, CB4211, in which researchers noted persistent injection-site reactions. FDA has not identified any human exposure data on drug products containing MOTS-c. Before a purchase, the Research Team sets out three checks: whether you fall into a group that should stay away, what a prescriber needs to weigh, and what the new US policy covers. Each is set out below with its source named.
What MOTS-c is, and what it is not
InCare describes MOTS-c as “a small peptide made of 16 amino acids” that comes from a part of the mitochondria called the 12S rRNA region. A 2023 review indexed on PubMed summarizes earlier work and describes it as a peptide hormone that “could reduce insulin resistance, prevent obesity, improve muscle function, promote bone metabolism, enhance immune regulation, and postpone aging” (2023 Metabolites review on PubMed).
The policy does not apply to products sold as research chemicals or dietary supplements, according to BakerHostetler’s summary of the policy.
Who may fit, and who should pause
Under the new US policy, a compounded MOTS-c product must be prescribed for you as an individual patient. So the first fit question is whether a prescriber will write one for you. InCare lists these groups as needing caution or avoidance:
| Group | What InCare says |
|---|---|
| Pregnant, breastfeeding, or planning pregnancy | Anyone in this group “should avoid this peptide entirely,” because there is no human reproductive safety data. |
| People taking insulin, sulfonylureas, or other glucose-lowering drugs | MOTS-c could cause “unpredictable blood sugar swings, including dangerous hypoglycemia.” |
| Significant kidney, liver, or heart disease, or uncontrolled hypertension | These groups are typically excluded from early peptide research. |
| Active cancer or autoimmune disease | Patients in these groups “should not use MOTS-c without a full evaluation.” |
| A known peptide allergy | Treat MOTS-c as a high-risk option. |
| Athletes subject to drug testing | InCare says the World Anti-Doping Agency lists MOTS-c under Section 4.4 of its prohibited list as an AMPK activator, banned at all times. |
If any row describes you, that is the first question for your prescriber.
What are the side effects of MOTS-c?
InCare lists these as “reported or theoretically possible side effects”:
| Possible side effect | Where it is listed |
|---|---|
| Injection-site redness, swelling, or irritation | InCare |
| Allergic or immune reactions | InCare |
| Changes in heart rate or palpitations | InCare |
| Trouble sleeping or insomnia | InCare |
| Fever | InCare |
| Low blood sugar, especially with diabetes medication | InCare |
InCare says the list draws on early studies, related peptide research and patient reports outside formal clinical settings. Treat these as possible effects InCare names, not as rates.
FDA placed MOTS-c in Category 2 (significant safety risks) of its list of bulk drug substances from September 2023 until April 22, 2026, when it was removed. In that earlier listing, FDA said compounded drugs containing MOTS-c “may pose significant risk for immunogenicity for certain routes of administration,” and that it had not identified any human exposure data for MOTS-c (FDA list of bulk substances with safety risks).
InCare also reports a short human study of a related analogue, CB4211, in which researchers noted persistent injection-site reactions.
Is MOTS-c safe for women?
The pregnancy and breastfeeding guidance is the part of the women’s question that matters most. InCare advises that anyone who is pregnant, breastfeeding, or planning pregnancy avoid it entirely, because there is no human reproductive safety data for it. If you are a woman who may become pregnant, raise this with your prescriber before any other step.
Cancer, heart and long-term questions
Cancer. InCare says MOTS-c’s impact on abnormal cell growth “is not well understood,” and it advises people with active cancer to avoid MOTS-c without a full evaluation. NBC News, citing the FDA, says the possible risks of the injectable peptides the FDA previously placed on its too-risky-to-compound list, which included BPC-157 and more than a dozen others, are contamination, allergic reactions and tumor growth (NBC News report on the peptide policy). For MOTS-c itself, the FDA’s list says it has not identified any human exposure data and that FDA lacks important information about whether MOTS-c would cause harm. For a comparable cancer-safety question about a different supplement, see research on whether melatonin causes cancer.
Heart. InCare lists heart-rate changes and palpitations among reported or possible effects, and it says people with a recent cardiac event or uncontrolled hypertension are typically excluded from early research. Its guidance is direct: “Anyone experiencing these symptoms should seek medical attention right away.”
Long-term use. Ask your prescriber how they would monitor you over months, and what they would do if a side effect appeared.
Does MOTS-c get rid of belly fat, and what are the benefits?
The 2023 review’s abstract talks about obesity in general, not belly fat. It presents its claims as possibilities that future work may develop, and it summarizes earlier work rather than reporting a new trial. A 2023 review in Frontiers in Physiology, indexed on PubMed, says that recent studies have revealed that MOTS-c “promotes osteoblast proliferation, differentiation, and mineralization” (2023 Frontiers review on bone metabolism).
If you are looking at before-and-after posts, the peptide before-and-after results (our research library) guide breaks down the photos, percentages and studies behind them.
How the new US policy affects MOTS-c
HHS published an interim enforcement discretion policy in the Federal Register notice on the peptide policy on October 30, 2026. Comments close November 13, 2026. MOTS-c is one of six peptides in its Appendix A. HHS says it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A, in the circumstances the policy lists.”
LegitScript, a third-party certification organization, says that “Enforcement discretion does not constitute FDA approval or establish that the compounded products are safe or effective.” FDA may revise or withdraw the policy at any time.
LegitScript’s summary of the policy says the conditions for MOTS-c are these:
- MOTS-c acetate, for subcutaneous or intramuscular use only.
- A patient-specific prescription.
- A single active ingredient.
- A certificate of analysis (COA) from a facility registered under section 510, with the original manufacturer’s physical location shown on it.
- A label reading “This is a compounded drug product. Not for resale.”
- Delivery devices limited to an FDA 510(k)-cleared syringe.
- Reporting of serious adverse events and product quality issues to FDA and the relevant states.
The policy does not cover 503B outsourcing facilities. LegitScript reads the single-ingredient condition to rule out combinations, so MOTS-c combined with another peptide does not qualify on that reading.
What does MOTS-c cost, and what do you commit to?
Prices for compounded peptides change and vary by prescriber and pharmacy. Check today’s price directly with the prescriber or pharmacy, and ask for the full cost of a course, including visits and shipping, in writing.
Is it legitimate? Scam checks before you pay
LegitScript updated its certification review effective November 2, 2026. It says certification “does not guarantee access to their services,” meaning advertising platforms and payment providers set their own rules. A seller’s certification therefore tells you little about whether its ads are sound.
LegitScript lists these signals that promotion has crossed a line:
- Claims about a peptide’s efficacy or safety, particularly compared with FDA-approved medications.
- Dosing recommendations for an unapproved drug.
- Specific treatment benefits, such as claims about a named condition.
- Describing a peptide as proven or scientifically backed without clear disclosure that most research has not been done in humans.
- Implying that a substance is FDA-approved, or cleared for compounding.
Partnership for Safe Medicines has filed a Partnership for Safe Medicines petition asking FDA not to allow compounding of peptides. In the same statement, it says the products it received came from pharmacies licensed in Texas and Pennsylvania, but none of those businesses had the licenses needed to dispense injectables in California.
Alternatives, including FDA-approved options and doing nothing
Doing nothing is a real choice, and nothing in the policy requires you to start. ABC News notes that “Some — like insulin and GLP-1s — are FDA-approved medicines that have been rigorously tested” (ABC News report on the July peptide vote). If your goal is metabolic, ask a clinician which options fit your situation.
A supplement is a different choice with different rules, and the policy excludes supplements. For one common supplement’s side effects, see lion’s mane mushroom supplement side effects.
Decision table: questions that settle it
| Question | What the answer means |
|---|---|
| Are you pregnant, breastfeeding, or planning pregnancy? | InCare says to avoid MOTS-c entirely. |
| Do you take insulin or another glucose-lowering drug? | InCare warns of possible low blood sugar; raise this with your prescriber first. |
| Has a prescriber written a prescription for you as an individual? | The policy requires a patient-specific prescription. |
| Is the product sold as a research chemical or supplement? | The policy does not cover these products. |
| Is the pharmacy a State-licensed pharmacy, a Federal facility or a licensed physician, rather than a 503B outsourcing facility? | The policy names State-licensed pharmacies, Federal facilities and licensed physicians; it does not cover 503B outsourcing facilities. |
| Is the product MOTS-c acetate, for subcutaneous or intramuscular use, with a single ingredient? | Those are the conditions LegitScript describes for MOTS-c. |
| Can the seller provide a certificate of analysis that shows the manufacturer’s location? | The policy requires a COA that shows this. |
How to verify before you pay
- Ask for the prescription in your name.
- Confirm the pharmacy is State-licensed and holds a license for injectables where you live.
- Ask for the certificate of analysis and check that it shows the manufacturer’s physical location.
- Check the label for “This is a compounded drug product. Not for resale.”
- Ask for refund, cancellation and renewal terms in writing before you pay.
Questions to ask your prescriber before you start
- How long does MOTS-c stay in the body, and how long before it starts to work? Ask what they expect and what that expectation is based on.
- What dose and how long a course? Those are the prescriber’s decisions, so ask them directly.
- Which human studies do you rely on? InCare names one human study, of the related analogue CB4211.
- How does the pharmacy report a serious side effect? The policy requires reporting to FDA and the relevant states.
For more on how peptide studies are designed and what they found, read peptides human studies (our research library).
Disclosure: This page includes affiliate offers, and HealthDataConsortium.org may earn a commission from some of them.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
